KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBT: 2009-2024

Historic EBT for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $18.4 million.

  • Rigel Pharmaceuticals' EBT rose 122.37% to $27.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.3 million, marking a year-over-year increase of 2846.02%. This contributed to the annual value of $18.4 million for FY2024, which is 173.20% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its EBT stood at $18.4 million for FY2024, which was up 173.20% from -$25.1 million recorded in FY2023.
  • Rigel Pharmaceuticals' EBT's 5-year high stood at $18.4 million during FY2024, with a 5-year trough of -$58.6 million in FY2022.
  • Moreover, its 3-year median value for EBT was -$25.1 million (2023), whereas its average is -$21.8 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' EBT plummeted by 238.40% in 2022, and later soared by 173.20% in 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' EBT (Yearly) stood at -$29.7 million in 2020, then soared by 41.81% to -$17.3 million in 2021, then plummeted by 238.40% to -$58.6 million in 2022, then spiked by 57.16% to -$25.1 million in 2023, then spiked by 173.20% to $18.4 million in 2024.